Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 17 November 2017

ESPERITE N.V. (ESP) , Stabilisation before growth.

Esperite N.V.    

Published: 08:18 CET 17-11-2017 /GlobeNewswire /Source: Esperite N.V. / : ESP /ISIN: NL0009272137

ESPERITE N.V. (ESP) , Stabilisation before growth.



Esperite has taken all the necessary measures after the difficult end of the first semester. The company invests in its technology and prepares to grow again.


Amsterdam, The Netherlands - 17 November 2017


Consolidated results


Consolidated revenues of the period are stable despite the common slow down of activity due to the summer. The company has increased the gross margin up to 60%. EDITDA has continued to improve during the period but remains negative. Opex is reduced by 10% compared to previous quarter.

The company continues its efforts of costs control and thanks to the contribution of external financing is able to implement a dynamic strategy of development. The total external investment during Q3 amounts to 1,350 Mio.


The new clients intake is increasing on a monthly basis as well as the average selling price of the services.

CryoSave has launched a new Premium Offer with high end features and expect an additional improvement in its sales and gross margin.


The company continues its territorial expansion and explores now a new market in Ukraine with a local partner. The company expect to announce soon other developments of its commercial footprint.

Esperite has successfully launched AGAATA, its exclusive Genetic Diagnostic System which embed proprietary technology now patented. AGAATA is a fully automated system providing clinical diagnostics in the fields of Prenatal, Reproductive Health, Oncology, Inherited Diseases. This system is CE-IVD and has been installed in 6 laboratories already, mostly public institutions.

Esperite achieves its new structure dedicated to the CDMO activity. The Contract Development Manufacture Organization business is the perfect opportunity for the group to grow with diversification. This development optimizes the usage of the existing laboratory and biobanking facilities. It will, as soon as Q1 2018, allow to generate additional revenues and profit from the existing infrastructures.


The Cell Factory and Output Pharma Services, along with CryoSave BioBank and Laboratories are the  key elements to this new CDMO business.




ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.comwww.genoma.com and www.cryo-save.com.

Q3 2017 Trading Update

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Esperite N.V., Piet Heinstraat 11a, Zutphen 7204 JN, The Netherlands
If you would like to unsubscribe and stop receiving these e-mails click here.